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ABSTRACT
CTX-M-type enzymes are a group of class A extended-spectrum b-lactamases (ESBLs) that are rapidly
spreading among Enterobacteriaceae worldwide. More that 50 allotypes are known, clustered into six
sub-lineages. The CTX-M-encoding genes have been captured from the chromosome of Kluyvera spp. on
conjugative plasmids that mediate their dissemination among pathogenic enterobacteria. CTX-M-type
ESBLs exhibit powerful activity against cefotaxime and ceftriaxone but generally not against
ceftazidime, which has important implications for laboratory detection. However, several CTX-M
variants with enhanced ceftazidimase activity have been detected. The rapid and massive spread of
CTX-M-type ESBLs is rapidly changing the ESBL epidemiology and, in some geographical areas, these
enzymes are now the most prevalent ESBLs in Enterobacteriaceae.
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INTRODUCTION
Among the ‘new’ b-lactamases emerging in Gram-
negative pathogens, the molecular class A ext-
ended-spectrum b-lactamases (ESBLs), active
against expanded-spectrum cephalosporins and
monobactams (but not against cephamycins or
carbapenems), are currently of great epidemio-
logical and clinical interest [1,2]. The dissemination
of these enzymes is a problem of globalmagnitude,
with rates of ESBL production being particularly
high in some enterobacterial species (e.g., Klebsiella
pneumoniae and Escherichia coli) and in some areas
(e.g., Europe and South America) [2].
The emergence of ESBLs followed the intro-
duction into clinical practice of expanded-spec-
trum cephalosporins, which are acknowledged to
be the most powerful selectors for these resistance
determinants. The spread of ESBLs represents a
major challenge to the activity of these drugs,
which were a milestone in antimicrobial chemo-
therapy of infections caused by Enterobacte-
riaceae and other Gram-negative pathogens [2].
Enterobacteriaceae have adopted two major
strategies for the production of ESBL activity:
(i) expansion of substrate speciﬁcity of the broad-
spectrum TEM- and SHV-type b-lactamases,
which were already widespread as acquired
b-lactamases in the clinical setting when
expanded-spectrum cephalosporins were intro-
ducted, by substitution of single or multiple
amino-acid residues at critical positions; and (ii)
capture of new genes encoding enzymes with
ESBL activity by horizontal transfer [3]. The latter
strategy became more prominent at a somewhat
later date (since the early 1990s), but has gained
an increasingly important role in the evolution of
ESBLs.
Several types of acquired ESBLs, other than
TEM and SHV mutants, have been described in
Enterobacteriaceae, including the CTX-M, VEB,
GES ⁄ IBC, PER, TLA, BES and SFO enzymes [2].
Among these, the CTX-M-type ESBLs are by far
the most successful in terms of spread and, in
several settings, their impact is currently compa-
rable to, or even greater than, that of TEM- and
SHV-type ESBLs. This review aims to provide an
overview of CTX-M-type ESBLs and their rapidly
increasing epidemiological and clinical impact.
CTX-M-TYPE b -LACTAMASES:
A RAPIDLY GROWING GROUP
CTX-M-type enzymes constitute a distinct lineage
of molecular class A b-lactamases, and are a
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rapidly growing group. The ﬁrst CTX-M-type
enzyme of clinical origin, CTX-M-1, was de-
scribed in enterobacterial strains isolated in
Europe in the late 1980s [4]. Thereafter, new
CTX-M variants have been described at an
increasing pace and, presently, more than 50
allelic variants are known, clustered in six sub-
lineages or groups. Each group is named after the
ﬁrst described member and, usually, includes
minor allelic variants that differ from each other
by single or a few amino-acid residues (Fig. 1).
CAPTURE AND SPREAD OF CTX-M-
TYPE b -LACTAMASE GENES IN THE
CLINICAL SETTING
Unlike for most other acquired ESBLs, the original
source of genes encoding CTX-M-type b-lacta-
mases is known. The sources of CTX-M determi-
nants are chromosomal genes resident in
members of the genus Kluyvera, which includes
a number of environmental species with little or
no pathogenic activity against humans. In part-
icular, precursors of genes encoding enzymes of
the CTX-M-1 and CTX-M-2 groups have been
detected in strains of Kluyvera ascorbata [4,5],
while precursors of genes encoding enzymes of
the CTX-M-8 and CTX-M-9 group occur in strains
of Kluyvera georgiana [4,6]. The original sources of
genes encoding members of the CTX-M-25 and
CTX-M-45 subgroups remain to be identiﬁed, but
most likely comprise other members of the genus
Kluyvera. Altogether, the heterogeneity of CTX-
M-type enzymes spreading in the clinical setting
among enterobacterial pathogens probably
reﬂects the occurrence of multiple independent
events of capture of blaCTX-M genes from
somewhat different sources within the Kluyvera
genus.
Multiple genetic mechanisms have apparently
been involved in the capture and dissemination of
CTX-M determinants. Genes encoding enzymes
of several CTX-M groups (CTX-M-1, CTX-M-2,
CTX-M-9 and CTX-M-25) have been found down-
stream of an ISEcp1 insertion sequence (Fig. 2),
a transposable element that can co-mobilise ﬂank-
ing DNA fragments via a one-ended transposition
mechanism. This was experimentally shown to be
able to mediate the capture of blaCTX-M genes from
the chromosomes of Kluyvera spp. and to facilitate
their inter-replicon mobility inside E. coli hosts
[7,8]. Genes encoding enzymes of some CTX-M
groups (CTX-M-2 and CTX-M-9) have also been
found within the so-called CR1 region associated
with some class 1 integrons (Fig. 2). ISEcp1 and
the recombination system associated with CR1
regions have probably played a major role in the
capture of blaCTX-M genes by conjugative plas-
mids, and in their further inter-replicon dissem-
ination, while the association of CR1 regions with
CTX-M-45
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Fig. 1. The six known sub-lineages (or groups) of CTX-M-type b-lactamases, shown in a tree diagram that reﬂects
similarity at the amino-acid sequence level. Filled triangles at the end of each branch indicate the presence of minor allelic
variants within the corresponding group. The tree was constructed with the TREEVIEW program (http://taxonomy.
zoology.gla.ac.uk/rod/treeview.html), based on a multiple sequence alignment of the publicly available CTX-M sequences
(http://www.lahey.org/Studies/). The degree of amino-acid sequence divergence among different groups ranges from
9.3% to 32% (or 25%, not considering the most divergent CTX-M-45 enzyme), being £3.5% within each group. CTX-M-14
is identical to CTX-M-18, and only the former is listed. Toho-1 corresponds to CTX-M-44, Toho-2 to CTX-M-45, UOE-1 to
CTX-M-15, and UOE-2 and Toho-3 to CTX-M-14.
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Tn402-like backbones could provide a further
mechanism of mobility for resistance genes.
Recently, a blaCTX-M-10 gene (CTX-M-9 group)
was detected within an original genetic context,
associated with phage-related sequences (Fig. 2),
suggesting that additional types of mobile ele-
ment might be involved in the mobilisation of
blaCTX-M genes.
The horizontal spread of blaCTX-M genes among
strains of the same or different enterobacterial
species is largely promoted by plasmids, which
often are self-conjugative and carry additional
resistance determinants [4].
FUNCTIONAL PROPERTIES OF CTX-
M-TYPE b -LACTAMASES
The CTX-M-type b-lactamases are natural ESBLs
that exhibit a striking substrate preference for
cefotaxime (and ceftriaxone) over ceftazidime
ISEcp1
blaCTX-M-15
IRi intI1
3’CS1
qacEΔ1 sul1
Gene cassettes
ISCR1 blaCTX-M-2
3’CS2
qacEΔ1 sul1   orf5
blaCTX-M-10
Phage related
DNA invertase
Similar to tnpA
from Tn1000
(a)
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Fig. 2. Examples of different genetic contexts of blaCTX-M genes. (a) blaCTX-M-15 located downstream of ISEcp1. A similar
arrangement has also been observed with several other blaCTX-M allotypes of the CTX-M-1, CTX-M-2, CTX-M-9 and CXT-
M-25 groups [4,33]. (b) blaCTX-M-2 located downstream of ISCR1, in association with a class 1 integron structure [4,34].
A similar arrangement has also been observed with several other blaCTX-M allotypes of the CTX-M-2 and CXT-M-9 groups
[34]. (c) blaCTX-M-10 in an unusual genetic context, associated with phage-related genes and insertion sequences [35].
Table 1. Catalytic efﬁciencies of CTX-M-type enzymes, representative of major groups, for some b-lactam substrates
Enzymes Group
kcat ⁄KM ( ⁄ s ⁄M)
PEN LOT CTX CAZ FEP ATM
CTX-M-3 CTX-M-1 >5 · 107 3 · 107 3 · 106 NH 1 · 103 1 · 106
CTX-M-8 CTX-M-8 1 · 107 2 · 107 1 · 106 <4 · 103 1 · 105 2 · 104
CTX-M-9 CTX-M-9 1 · 107 2 · 107 4 · 106 3 · 103 ND 5 · 104
CTX-M-44 CTX-M-2 3 · 106 1 · 107 2 · 106 1 · 103 7 · 104 ND
PEN, penicillin G; LOT, cephalothin; CTX, cefotaxime; CAZ, ceftazidime; FEP, cefepime; ATM, aztreonam; NH, no
detectable hydrolysis; ND, no data available.
Data are from [4] and [13]
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(Table 1). Their strong cefotaximase activity is
related to the unique geometry of the b-lactam-
binding site, which allows efﬁcient recognition of
penicillins, narrow-spectrum cephalosporins and
cefotaxime, but not of the bulkier ceftazidime
molecule [9,10].
The peculiar substrate speciﬁcity of CTX-M-
type enzymes has important implications for
laboratory detection. Strains of Enterobacteriaceae
with CTX-M enzymes normally appear to be
resistant or exhibit reduced susceptibility to cef-
otaxime (also to ceftriaxone and cefpodoxime)
and are readily detected as potential ESBL pro-
ducers using the CLSI breakpoints indicating
suspicion of ESBL production [11], whereas they
often appear to be susceptible to ceftazidime, with
MIC values and inhibition zone sizes, respec-
tively, lower or larger than the CLSI breakpoints
indicating suspicion of ESBL production. There-
fore, to ensure that no isolate with CTX-M
enzymes is missed, cefotaxime (or ceftriaxone or
cefpodoxime) must always be included, in addi-
tion to ceftazidime, in screening for the presence
of ESBL producers in the clinical microbiology
laboratory.
Modulation of the substrate spectrum of CTX-
M-type enzymes by point mutations is possible,
similar to what happens with the TEM- and SHV-
type enzymes [3]. In particular, a number of CTX-
M mutants with increased ceftazidimase activity
have been described. These have probably been
selected by the massive use of ceftazidime in
clinical practice [4,12,13]. The mutations in these
variants occur in two of the structural elements
that delimit the b-lactam-binding site, namely the
terminal part of the B3 b-strand and the W-loop
(Fig. 3). The Asp240 ﬁ Gly substitution in the
terminal part of the B3 b-strand is responsible for
increased ﬂexibility of the b-strand, rendering the
active site more accessible to the bulkier ceftazi-
dime molecule [9], while the substitutions in the
X-loop (at position 167) apparently modify the
mode of interaction of b-lactams with the binding
site [14]. Overall, these mutations result in a
Ω loop167 240
Ser *
α2
β3
Fig. 3. Modulation of the substrate spectrum of CTX-M-type enzymes by point mutations. The structure of a CTX-M-type
enzyme (CTX-M-9; PDB entry 1YLJ) is shown here as a ribbon diagram generated with the DEEPVIEW program (http://
www.expasy.org/spdbv/). As with other serine b-lactamases, the overall molecular fold consists of an a-helical domain
(on the left side) and a mixed a ⁄ b-domain (on the right side). The b-lactam-binding site, indicated by an arrow, is located in
a cleft between the two domains. Positions 167 and 240, where amino-acid substitutions enhancing ceftazidimase activity
occur, are located either in the X-loop (in green, at the bottom of the binding site) or in the terminal part of the B3 b-strand
(b3, in red, on the right side of the binding site), and are shown by red dots. The active site serine residue (Ser*) in the active
site, located at the end of H2 a-helix (a2, in yellow), is also shown. The Asp240 ﬁ Gly substitution should increase the
ﬂexibility of the B3 b-strand, rendering the active site more accessible to the bulkier ceftazidime molecule [9]. The
Pro167 ﬁ Ser substitution in the X-loop is thought to modify the mode of interaction of b-lactams with the binding site,
allowing better recognition of ceftazidime but impairing recognition of some other substrates [14].
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modest increase in the catalytic efﬁciency of the
enzyme against ceftazidime [4,12,13]. Neverthe-
less, this is sufﬁcient to signiﬁcantly increase
the ceftazidime MICs for the strains producing
the mutant enzymes (Table 2). Unlike the
Asp240 ﬁ Gly substitution, which does not sig-
niﬁcantly affect the activity of the enzyme against
other b-lactam substrates, the substitutions in the
X-loop are associated with a signiﬁcant decrease
in the catalytic efﬁciency of the enzyme for other
substrates [4,12,13], which is also reﬂected in the
corresponding MIC values (Table 2). This could
account, at least in part, for the fact that the
Asp240 ﬁ Gly substitution has apparently been
selected more frequently than mutations in the
X-loop.
THE 1960s EPIDEMIOLOGY OF
CTX-M-TYPE b -LACTAMASES
Strains producing CTX-M-type ESBLs were
ﬁrst reported, sporadically, in the late 1980s in
Japan, Europe and Argentina [4]. In the early
1990s, a massive spread of CTX-M-producing
strains occurred in Argentina and neighbour-
ing countries. This regional CTX-M epidemic
involved several enterobacterial species (including
Salmonella enterica, Proteus mirabilis, E. coli, Shigella
sonnei, Morganella morganii, Citrobacter freundii,
Serratia marcescens and Enterobacter aerogenes)
and, mostly, allotypes of the CTX-M-2 group [4].
During the past 15 years, CTX-M-type ESBLs
have undergone a rapid and global spread.
Enterobacterial strains producing these enzymes
have now been reported almost everywhere
(Fig. 4) and, in some settings, CTX-M-type
enzymes outnumber the classic TEM- and SHV-
type ESBLs [15,16]. This massive worldwide
dissemination, which could be referred to as the
‘CTX-M pandemic’, is one of the most striking
examples of rapid and global dissemination of
plasmid-mediated resistance determinants among
bacterial pathogens, and has been compared to
the dissemination of the broad-spectrum TEM-
type b-lactamases observed since the 1960s. The
reason(s) for such an explosive dissemination of
CTX-M-type ESBLs in Enterobacteriaceae re-
main(s) to be clariﬁed. Carriage on plasmids that
are highly efﬁcient at conjugal transfer, and ⁄ or a
lower ﬁtness cost imposed by these enzymes and
cognate genetic elements upon the bacterial hosts
(as compared with other types of ESBLs), could be
included among the possible explanations for the
remarkable success of CTX-M-type enzymes, as
Table 2. Susceptibility to various b-lactams of Escherichia coli strains producing CTX-M derivatives with enhanced
ceftazidimase activity, in comparison with that of E. coli strains producing the parent enzymes
E. coli strains Enzymes
MICs (mg ⁄L)
CTX CAZ FEP ATM
DH10Ba None £0.06 £0.06 £0.06 0.06
DH10B CTX-M-3 >256 32 128 128
DH10B CTX-M-15
(CTX-M-3 Asp240 ﬁ Gly)
>256 256 64 64
J53 CTX-M-54
(CTX-M-3 Pro167 ﬁ Gln)
8 128 1 2
TG1 CTX-M-1 >128 6 48 48
TG1 CTX-M-32
(CTX-M-1 Asp240 ﬁ Gly)
>128 >256 64 >256
DH5a CTX-M-9 16 1 ND 4
DH5a CTX-M-16
(CTX-M-9 Asp240 ﬁ Gly)
16 8 ND 8
JM109 CTX-M-18 64 2 16 64
JM109 CTX-M-19
(CTX-M-18 Pro167 ﬁ Ser)
4 128 4 4
aThe b-lactam susceptibility of E. coli DH10B, as a representative host not producing b-lactamase activity, is shown for
comparison.
ND, no data available.
CTX, cefotaxime; CAZ, ceftazidime; FEP, cefepime; ATM, aztreonam.
Data are from [4] (for the CTX-M-3 ⁄CTX-M-15, CXT-M-9 ⁄CTX-M-16 and CTX-M-14 ⁄CTX-M-19 pairs), from [15] (for the
CTX-M-1 ⁄CTX-M-32 pair) and from [16] (for CTX-M-54).
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compared with other types of ESBLs. However,
these issues remain to be clariﬁed and would
constitute an interesting subject for future inves-
tigations.
In recent surveillance studies, high rates of
CTX-M enzymes among ESBL-producing E. coli
and K. pneumoniae isolates have been reported
from South America, Asia and Europe, while a
lower impact has been observed in Canada
(Table 3). In some of those settings, rates of
CTX-M-production as high as 89.7% in E. coli
and 58.5% in K. pneumoniae have been reported
(Table 3).
In Europe, where the TEM- and SHV-type
ESBLs were ﬁrst described and have played a
major role as ESBL determinants [3], the CTX-M-
type ESBLs have recently achieved a remarkable
diffusion in several countries. The spread of
Uncharacterized CTX-M type
CTX-M-2 group
CTX-M-9 group
CTX-M-25 group
CTX-M-8 group
CTX-M-1 group
CTX-M-45 group
Fig. 4. World map showing locations where clinical isolates of Enterobacteriaceae producing CTX-M-type extended-
spectrum b-lactamases have been reported. Data are according to Reference [4] and the subsequent literature available on
the PubMed database (http://www.pubmed.com).
Table 3. Rates of isolates with
CTX-M enzymes, among extended-
spectrum b-lactamase (ESBL)-pro-
ducing Escherichia coli and Klebsiella
pneumoniae isolates, as reported in
recent surveillance studies
Country Year(s) E. coli (%) K. pneumoniae (%) References
Russia 1997–1998 35.9 35.0 [17]
Canada 2000 6.3 13.7a [36]
Argentina 2000 80.0 50.0 [37]
Spain 2002 52.3 12.5 [19]
Italy 2003 54.8 12.3 [20]
Taiwan 2003 89.7 58.5 [16]
South Korea 2003 30.4 32.7 [38]
aKlebsiella spp.
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CTX-M-producing strains was ﬁrst reported in
eastern Europe [4,17], but has subsequently
involved also western and southern European
countries. One of the most striking examples of
rapid dissemination of these ESBLs has been
reported in the UK, where CTX-M enzymes were
ﬁrst reported in 2000 and have subsequently
undergone an explosive spread involving E. coli
and also K. pneumoniae, with a predominance of
group 1 enzymes (mostly CTX-M-15) [18]. In the
London area, E. coli resistance to expanded-
spectrum cephalosporins increased from 1.8%
in 2001 to 7.5% in 2004, largely as a consequence
of the diffusion of CTX-M-type ESBLs [18],
raising considerable concern, since E. coli is one
of the most common species isolated from
clinical samples. A remarkable diffusion of
CTX-M-type ESBLs has also been observed in
the most recent nationwide surveys of ESBL
production carried out in Spain [19] and Italy
[20]. In Spain, rates of production of CTX-M
enzymes were found to be 52.3% and 12.5%
among ESBL-producing isolates of E. coli and
K. pneumoniae, respectively, with a predominance
of group 9 (CTX-M-9 and CTX-M-14) and
group 1 (CTX-M-10) [19]. In Italy, the rates of
CTX-M production were found to be 54.8% and
12.3% among ESBL-producing isolates of E. coli
and K. pneumoniae, respectively, with an absolute
predominance of group 1 enzymes (mostly
CTX-M-1 and CTX-M-15 and, less frequently,
CTX-M-32) [20,21]. High-rates of CTX-M
enzymes have also been reported in Greek
hospitals [15], and the presence of CTX-M-type
ESBLs of various groups has been well-docu-
mented in other European countries, including
France, Austria and Sweden [22–24].
The progressive change in the epidemiology of
ESBLs due to the spread of CTX-M-type enzymes
has been clearly documented in two longitudinal
studies, carried out at a regional level, in northern
Italy and in Austria [23,25]. In those areas, the
prevalence of CTX-M enzymes among ESBL-
producing E. coli was found to be low or nil at
the beginning of the surveillance period (12.5% in
Italy in 1999; 0% in Austria in 1998), but a steady
increase in prevalence was observed during the
following years, concluding with rates that were
as high as 38.2% of all ESBLs in Italy in 2003 and
85% in Austria in 2004, respectively. Notably, the
increase of CTX-M enzymes in E. coli as com-
pared with other ESBL types did not reﬂect a
relative, but rather an absolute, increase in the
former isolates.
Although originally conﬁned to hospitals,
ESBL-producing strains are now emerging also
in the community [26]. This is an alarming
phenomenon that could have major implications
for antimicrobial chemotherapy. Most ESBL-pro-
ducing isolates that cause community-acquired
infections have been E. coli, with CTX-M-type
b-lactamases [26]. In a recent study, producers of
CTX-M enzymes were found to be involved in
eight of ten cases of bacteraemia caused by
community-acquired ESBL-producing enterobac-
teria [27].
Another relevant issue in the epidemiology of
ESBL-producing Enterobacteriaceae (especially
E. coli) is their presence in the commensal mic-
robiota of humans. Here again, the CTX-M-type
ESBLs appear to play a consistent role. In a recent
study from Spain, rates of faecal carriage of
ESBL-producing E. coli during non-outbreak sit-
uations were found to be as high as 11.8% among
inpatients and 5.5% among outpatients, while
42% and 69% of the ESBL-positive isolates,
respectively, had CTX-M-type enzymes [28].
In another recent study, carried out in Israel, a
10.8% rate of faecal carriage of ESBL-positive
isolates was found upon hospital admission, and
most of the community-acquired isolates pro-
duced a CTX-M-type enzyme [27]. The risk of
developing subsequent bacteraemia caused by an
ESBL-producing strain was found to be signiﬁ-
cantly higher in colonised vs. non-colonised
patients [27]. Finally, E. coli isolates with CTX-
M enzymes have also been detected in samples
from livestock [29,30] and companion animals
[31], showing that animals might act as an
important reservoir.
CLINICAL IMPACT OF CTX-M-TYPE
b -LACTAMASES
Overall, production of CTX-M-type b-lactamases
has the same clinical implications as production
of other ESBLs, leaving carbapenems as the only
reliable b-lactams for treatment of serious infec-
tions caused by producer pathogens [2]. Similar
to what was observed with enterobacterial strains
producing TEM- and SHV-type ESBLs, high-rates
of co-resistance to potentially active drugs, e.g.,
ﬂuoroquinolones and aminoglycosides, have also
been reported for strains with CTX-M enzymes.
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In the most recent nationwide survey carried out
in Italy, the gentamicin- and ciproﬂoxacin-resis-
tant rates, among E. coli with CTX-M enzymes,
were 62% and 19%, respectively [21].
Although carbapenems are stable to CTX-M-
type enzymes, the emergence of resistance during
carbapenem therapy has recently been reported in
a K. pneumoniae strain producing the CTX-M-15
enzyme, following the loss of an outer-membrane
porin [32]. Such mutations tend to be rapidly lost
in the absence of a selective pressure; however,
the possibility of selection of carbapenem-resis-
tant mutants of ESBL-producing Enterobacteria-
ceae during carbapenem therapy is a matter of
concern, due to the increasing prevalence of these
enzymes and to the limited number of therapeutic
alternatives.
CONCLUDING REMARKS
The CTX-M-type ESBLs have recently undergone
a rapid and global spread in Enterobacteriaceae.
This CTX-M ‘epidemic’ is changing the epidemi-
ology of ESBLs and, in several settings, the CTX-
M-type ESBLs are now the most prevalent ESBLs
encountered in E. coli and K. pneumoniae. The
propensity of CTX-M-encoding genes to rapidly
spread in E. coli is a matter of major concern,
considering that this is one of the most common
species isolated from clinical samples. Dissemi-
nation of the CTX-M-type ESBLs is not restricted
to the nosocomial setting but also involves the
community. This phenomenon is acting to modify
the epidemiology of ESBLs, whereas those en-
zymes were, previously, mostly restricted to the
nosocomial setting.
The CTX-M-type b-lactamases exhibit a
remarkable allotypic diversity, and their genes
occur in a notable variety of genetic contexts. Both
these features, and especially the latter, could
account for the rapid dissemination exhibited by
these resistance determinants. Evolution of sub-
strate speciﬁcity by point mutations is also pos-
sible, as with TEM- and SHV-type b-lactamases.
The spread of CTX-M-type ESBLs is causing
rapid, important and unpredictable changes in
the epidemiology of antibiotic resistance. It
underlines the need for strict surveillance. In this
regard, it should be emphasized that testing
molecules such as cefotaxime, ceftriaxone and ⁄ or
cefpodoxime is essential for laboratory detection
of isolates producing CTX-M enzymes, and that
testing ceftazidime as the sole representative of
expanded-spectrum cephalosporins can lead to
false-negative results, thereby underestimating
the prevalence of ESBL producers.
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